Back to Results
First PageMeta Content
Emerging technologies / Gene delivery / Medical genetics / Medical research / Molecular biology / Gene therapy / Macular degeneration / Retina / Choroideremia / Biology / Medicine / Ophthalmology


AAV : Virus meets Vector meets Host
Add to Reading List

Document Date: 2014-01-13 09:17:22

Open Document

File Size: 318,22 KB

Share Result on Facebook

City

Perth / /

Company

GlaxoSmithKline / Oxford Biomedica / Novartis / Sanofi / GenSight Biologicals Gene / ReGenX Biosciences / Genzyme / /

Event

FDA Phase / Natural Disaster / /

Facility

Regulated Expression Building / Oregon Moorfield Eye Hospital / University College London University of Florida/University / Delivery Building / Lions Eye Institute / Israel Casey Eye Institute / Moorfield Eye Hospital / University College London Oxford Biomedica Oxford Biomedica / Pennsylvania University / Children’s Hospital of Philadelphia Hadassah Medical Center / /

IndustryTerm

Therapy For Ocular Diseases / pharmaceutical / /

MedicalCondition

I (ongoing) Age Related Macular Degeneration / Stargardt Disease / eye disorders / hereditary disease / wet form Age Related Macular Degeneration / diseases / AR Age Related Macular Degeneration / AR Usher 1b Retinitis Pigmentosa / eye diseases / /

MedicalTreatment

Gene Therapy / /

Organization

University of Pennsylvania University / Avalanche Bio and Lions Eye Institute / National Institute of Health / Oregon Moorfield Eye Hospital / University College London University / Harvard / Philadelphia Hadassah Medical Center / Indication Gene Vector ROA Stage Center / Moorfield Eye Hospital / Israel Casey Eye Institute / University of Florida / /

Person

Luk H. Vandenberghe / Clyde Keeler / Gene Vector / /

Position

Investigator / Co-Founder / AR Usher / /

Product

Subretinal Injection / AdV5 / MYO7a / AAV2 / /

ProvinceOrState

Pennsylvania / Florida / /

Technology

Gene Therapy / Genomics / Pharmacokinetics / /

SocialTag